Clinical Trial Update: ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating ZD6474 (vandetanib) alone or in combination with paclitaxel and carboplatin as first-line the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• ZD6474 (vandetanib) (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED